| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
COLL Stock Overview
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.
Collegium Pharmaceutical Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.54 |
| 52 Week High | US$26.91 |
| 52 Week Low | US$17.22 |
| Beta | 0.97 |
| 1 Month Change | -6.45% |
| 3 Month Change | -16.71% |
| 1 Year Change | -25.74% |
| 3 Year Change | 15.02% |
| 5 Year Change | 13.90% |
| Change since IPO | 42.72% |
Recent News & Updates
We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Sizing Up Collegium Pharmaceuticals
Today, we revisit Collegium Pharmaceuticals for the first time since March of last year. The company is doing a good job of reducing debt and recently announced a substantial stock buyback program. A full investment analysis follows in the paragraphs below.
Shareholder Returns
| COLL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.3% | -2.2% | -4.0% |
| 1Y | -25.7% | 7.1% | 6.6% |
Return vs Industry: COLL underperformed the US Pharmaceuticals industry which returned 6.7% over the past year.
Return vs Market: COLL underperformed the US Market which returned 7.7% over the past year.
Price Volatility
| COLL volatility | |
|---|---|
| COLL Average Weekly Movement | 4.6% |
| Pharmaceuticals Industry Average Movement | 10.6% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: COLL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: COLL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 234 | Joe Ciaffoni | https://www.collegiumpharma.com |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical Fundamentals Summary
| COLL fundamental statistics | |
|---|---|
| Market Cap | US$610.34m |
| Earnings (TTM) | US$103.51m |
| Revenue (TTM) | US$325.78m |
5.9x
P/E Ratio1.9x
P/S RatioIs COLL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COLL income statement (TTM) | |
|---|---|
| Revenue | US$325.78m |
| Cost of Revenue | US$62.35m |
| Gross Profit | US$263.42m |
| Expenses | US$159.91m |
| Earnings | US$103.51m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.97 |
| Gross Margin | 80.86% |
| Net Profit Margin | 31.77% |
| Debt/Equity Ratio | 104.2% |
How did COLL perform over the long term?
See historical performance and comparisonValuation
Is Collegium Pharmaceutical undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: COLL ($17.54) is trading below our estimate of fair value ($102.22)
Significantly Below Fair Value: COLL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: COLL is good value based on its PE Ratio (5.9x) compared to the US Pharmaceuticals industry average (23.1x).
PE vs Market: COLL is good value based on its PE Ratio (5.9x) compared to the US market (16.9x).
Price to Earnings Growth Ratio
PEG Ratio: COLL's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: COLL is overvalued based on its PB Ratio (2.4x) compared to the US Pharmaceuticals industry average (2.2x).
Future Growth
How is Collegium Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
-11.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COLL's earnings are forecast to decline over the next 3 years (-11.6% per year).
Earnings vs Market: COLL's earnings are forecast to decline over the next 3 years (-11.6% per year).
High Growth Earnings: COLL's earnings are forecast to decline over the next 3 years.
Revenue vs Market: COLL's revenue (1.6% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: COLL's revenue (1.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if COLL's Return on Equity is forecast to be high in 3 years time
Past Performance
How has Collegium Pharmaceutical performed over the past 5 years?
66.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: COLL has high quality earnings.
Growing Profit Margin: COLL's current net profit margins (31.8%) are higher than last year (5.7%).
Past Earnings Growth Analysis
Earnings Trend: COLL has become profitable over the past 5 years, growing earnings by 66.6% per year.
Accelerating Growth: COLL's earnings growth over the past year (488.4%) exceeds its 5-year average (66.6% per year).
Earnings vs Industry: COLL earnings growth over the past year (488.4%) exceeded the Pharmaceuticals industry 12.2%.
Return on Equity
High ROE: Whilst COLL's Return on Equity (41.22%) is outstanding, this metric is skewed due to their high level of debt.
Financial Health
How is Collegium Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: COLL's short term assets ($363.2M) exceed its short term liabilities ($269.0M).
Long Term Liabilities: COLL's short term assets ($363.2M) exceed its long term liabilities ($221.7M).
Debt to Equity History and Analysis
Debt Level: COLL's net debt to equity ratio (27.3%) is considered satisfactory.
Reducing Debt: COLL's debt to equity ratio has increased from 6.4% to 104.2% over the past 5 years.
Debt Coverage: COLL's debt is well covered by operating cash flow (34.4%).
Interest Coverage: COLL's interest payments on its debt are not well covered by EBIT (2.8x coverage).
Balance Sheet
Dividend
What is Collegium Pharmaceutical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate COLL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate COLL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if COLL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if COLL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of COLL's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.1yrs
Average management tenure
CEO
Joe Ciaffoni (50 yo)
3.5yrs
Tenure
US$6,042,639
Compensation
Mr. Joseph J. Ciaffoni, also known as Joe, has been Chief Executive Officer and Director of Collegium Pharmaceutical, Inc. since July 1, 2018 and also has been its President since July 2018. Mr. Ciaffoni s...
CEO Compensation Analysis
Compensation vs Market: Joe's total compensation ($USD6.04M) is above average for companies of similar size in the US market ($USD2.40M).
Compensation vs Earnings: Joe's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: COLL's management team is considered experienced (3.1 years average tenure).
Board Members
Experienced Board: COLL's board of directors are considered experienced (7.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Collegium Pharmaceutical, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Collegium Pharmaceutical, Inc.
- Ticker: COLL
- Exchange: NasdaqGS
- Founded: 2002
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$610.342m
- Shares outstanding: 34.80m
- Website: https://www.collegiumpharma.com
Number of Employees
Location
- Collegium Pharmaceutical, Inc.
- 100 Technology Center Drive
- Suite 300
- Stoughton
- Massachusetts
- 2072
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/21 00:03 |
| End of Day Share Price | 2022/01/20 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.